PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Current and Emerging Radiopharmaceuticals for Prostate Cancer: Is There a Role for Both?
Visit https://www.peervoice.com/DYY860 to view the entire programme with slides. After completing “Current and Emerging Radiopharmaceuticals for Prostate Cancer: Is There a Role for Both?”, participants will be able to: Explain the rationale for radiopharmaceuticals as active lines of treatment for men with metastatic prostate cancer (mPC); Appraise how the clinical data and real-world evidence for radiopharmaceuticals may inform the individualised management of men with mPC now and in the future; Propose individualised treatment plans for men with mPC who are suitable for radiopharmaceuticals.